Related Experiment Video
Updated: Dec 7, 2025
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Arsenic trioxide as a novel anti-glioma drug: a review
1Department of Ultrasound, First Affiliated Hospital of China Medical University, Shenyang, 110001 Liaoning People's Republic of China.
Abstract:
Arsenic trioxide has shown a strong anti-tumor effect with little toxicity when used in the treatment of acute promyelocytic leukemia (APL). An effect on glioma has also been shown. Its mechanisms include regulation of apoptosis and autophagy; promotion of the intracellular production of reactive oxygen species, causing oxidative damage; and inhibition of tumor stem cells. However, glioma cells and tissues from other sources show different responses to arsenic trioxide. Researchers are working to enhance its efficacy in anti-glioma treatments and reducing any adverse reactions. Here, we review recent research on the efficacy and mechanisms of action of arsenic trioxide in the treatment of gliomas to provide guidance for future studies.
Insights
Arsenic trioxide shows promise for treating gliomas by regulating cell death and damaging tumor stem cells. Further research aims to improve its effectiveness and reduce side effects in glioma treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Arsenic trioxide demonstrates anti-tumor properties with low toxicity, notably in acute promyelocytic leukemia (APL).
- Preliminary evidence suggests arsenic trioxide also impacts glioma, a type of brain tumor.
Purpose of the Study:
- To review the efficacy and mechanisms of arsenic trioxide in glioma treatment.
- To guide future research for enhanced anti-glioma therapies.
Main Methods:
- Review of recent scientific literature on arsenic trioxide and glioma.
- Analysis of proposed mechanisms of action, including apoptosis, autophagy, oxidative stress, and tumor stem cell inhibition.
Main Results:
- Arsenic trioxide exhibits anti-glioma effects through multiple pathways.
- Variability in glioma cell and tissue response to arsenic trioxide necessitates further investigation.
- Ongoing research focuses on optimizing arsenic trioxide efficacy and minimizing adverse reactions.
Conclusions:
- Arsenic trioxide holds potential as an anti-glioma therapeutic agent.
- Understanding its diverse mechanisms is crucial for clinical application.
- Future studies should address response variability and therapeutic optimization.
